1. Home
  2. /
  3. Projects

TAG

Protecting investment in TB vaccine R&D and health systems amid debt distress and reform

IMF analysis reveals 51 countries with moderate-to-high risk of sovereign debt distress and 9 countries in debt distress: unable to fulfill financial obligations to lenders. For many high-TB burden countries, yearly debt servicing now exceeds domestic revenue – forcing countries to cut expenditure on health. Based on a literature review and engagement with World Bank/IMF, this abstract presents a policy analysis of the implications of sovereign debt distress on TB vaccine readiness and proposes debt relief and reform as innovative financial tools for creating fiscal space for government investment in vaccine R&D and implementation

Scoping Community Interventions to Support New TB Vaccine Introduction: From Grassroots Partnerships to Global Policymaking

To assess the role of communities and civil society in shaping TB vaccine introduction policies, implementation and equitable access. Aim 1: Map the structures, networks, and major players active in TB civil society and overlay these with the policy pipeline for new TB vaccines. Aim 1: Map the structures, networks, and major players active in TB civil society and overlay these with the policy pipeline for new TB vaccines. Aim 2: work with members of the regional community advisory boards (rCABs) established with support from the USAID-funded SMART4TB project to produce country policy portraits illustrating how TB and immunization policy is made in selected countries and the points where community and civil society actors can intervene. Aim 3: work with the rCAB in the Eastern Europe and Central Asia (EECA) region to explore interventions by community and civil society to ensure equitable access to new TB vaccines. All three Aims will be completed in relation to the ECVP and the Global Framework for Country Introduction of New TB Vaccines.

Tuberculosis Vaccine Accelerator Council

In January 2023, WHO’s Director-General announced plans to establish a TB vaccine accelerator Council to facilitate the development, testing, authorization, and use of new TB vaccines, drawing on lessons learned from the response to the COVID-19 pandemic. The establishment meeting of the Council took place on 20 September 2023, on the occasion of the 78th session of the United Nations General Assembly, in the lead up to the Second United Nations High-level Meeting on TB.The Council is anticipated to work in multiple ways. These includeidentifying needs for, and types of innovative sustainable financial solutions, as well as partnerships between the public, private and philanthropic sectors that can expedite the translation of science into TB vaccines, and ensure their equitable access once available; identifying market solutions to incentivize TB vaccine development, and to ensure that the R&D ecosystem is positioned to rapidly manufacture and distribute vaccines equitably and at scale, once they are available; and advocating with decision makers in the public, private, philanthropy and other relevant sectors to strengthen commitment and concerted action to develop and expand access to novel effective TB vaccines, including through political platforms such as the African Union, ASEAN, BRICS, G20, G7 and others.

Financing and policy innovation to advance TB vaccines through licensure: A G20 policy proposal

The authors developed two T20 policy briefs proposing recommendations to enhance G20 leadership and bring TB vaccines through licensure: Investment Toolbox to Advance TB Vaccine R&D through Joint Action (2023); and Elevating Leadership of HBC G20 States in TB Vaccine R&D and Delivery (2024). The briefs were informed by extensive literature research and aligned with global initiatives for TB and TB vaccine R&D.

TB vaccine advocacy roadmap

The TB Vax ARM represents a global coalition of TB stakeholders, including TB survivors, civil society organizations, and non-profits, invested in TB vaccine advocacy and research, and seeks to provide coordinated advocacy efforts that are complementary to ongoing TB vaccine R&D and policy efforts. The TB Vax ARM holds regular virtual calls with partners and guest speakers from around the world. WGNV coordinates with the TB Vax ARM on global advocacy activities. For more information go to: https://newtbvaccines.org/take-action/
Click to copy link of this header Menu